Trevena Inc (TRVN) Stake Decreased by Fmr LLC

FMR LLC cut its stake in shares of Trevena Inc (NASDAQ:TRVN) by 13.9% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The firm owned 6,733,548 shares of the biopharmaceutical company’s stock after selling 1,084,200 shares during the period. FMR LLC owned about 12.87% of Trevena worth $39,594,000 as of its most recent filing with the SEC.

Other large investors have also recently made changes to their positions in the company. Wells Fargo & Company MN boosted its stake in shares of Trevena by 51.9% in the third quarter. Wells Fargo & Company MN now owns 15,393 shares of the biopharmaceutical company’s stock valued at $104,000 after buying an additional 5,261 shares during the last quarter. National Planning Corp boosted its stake in shares of Trevena by 7.8% in the fourth quarter. National Planning Corp now owns 21,512 shares of the biopharmaceutical company’s stock valued at $162,000 after buying an additional 1,560 shares during the last quarter. Piermont Capital Management Inc. purchased a new stake in shares of Trevena during the third quarter valued at approximately $529,000. Russell Investments Group Ltd. purchased a new stake in shares of Trevena during the fourth quarter valued at approximately $483,000. Finally, Baker BROS. Advisors LP bought a new stake in shares of Trevena during the third quarter worth about $3,038,000. 69.28% of the stock is owned by institutional investors and hedge funds.

Institutional Ownership by Quarter for Trevena (NASDAQ:TRVN)

Shares of Trevena Inc (NASDAQ:TRVN) traded down 2.08% on Friday, hitting $3.29. The company had a trading volume of 452,603 shares. The firm has a 50-day moving average price of $3.59 and a 200 day moving average price of $5.37. Trevena Inc has a 12-month low of $3.23 and a 12-month high of $8.38. The company’s market capitalization is $187.95 million.

Trevena (NASDAQ:TRVN) last released its quarterly earnings data on Wednesday, March 8th. The biopharmaceutical company reported ($0.67) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.62) by $0.05. Trevena had a negative return on equity of 66.50% and a negative net margin of 841.00%. During the same period in the previous year, the company posted ($0.30) earnings per share. Equities analysts expect that Trevena Inc will post ($1.72) EPS for the current year.

WARNING: “Trevena Inc (TRVN) Stake Decreased by Fmr LLC” was originally published by Community Financial News and is the property of of Community Financial News. If you are viewing this report on another website, it was illegally copied and republished in violation of U.S. and international copyright law. The original version of this report can be accessed at https://www.com-unik.info/2017/04/21/fmr-llc-has-39594000-stake-in-trevena-inc-trvn-updated-updated.html.

A number of brokerages have issued reports on TRVN. Aegis reaffirmed a “buy” rating and set a $14.00 target price on shares of Trevena in a research report on Monday. Needham & Company LLC reaffirmed a “buy” rating and set a $11.00 target price on shares of Trevena in a research report on Wednesday, April 5th. Zacks Investment Research raised Trevena from a “sell” rating to a “hold” rating in a research report on Wednesday, March 29th. Oppenheimer Holdings Inc. reaffirmed a “buy” rating on shares of Trevena in a research report on Wednesday, March 22nd. Finally, Cowen and Company reaffirmed a “buy” rating and set a $13.00 target price on shares of Trevena in a research report on Wednesday, March 22nd. One analyst has rated the stock with a sell rating, one has assigned a hold rating and eleven have assigned a buy rating to the stock. The stock currently has an average rating of “Buy” and a consensus price target of $11.73.

Trevena Company Profile

Trevena Inc is a biopharmaceutical company, which is engaged in developing various therapies. The Company is developing OLINVO, a u-receptor G protein pathway selective modulator (u-GPS) for the management of moderate-to-severe acute pain where intravenous (IV) administration is preferred. It is focused on commercializing it in the United States for use in acute care settings, such as hospitals and ambulatory surgery centers.

5 Day Chart for NASDAQ:TRVN

What are top analysts saying about Trevena Inc? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Trevena Inc and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit